📜 iter-4360dd15-0043.log
23566 bytes
# Iter-0043 mission=4360dd15
# goal: 找到让人类长生不老的方法
# time: 2026-04-26T00:48:05
# focus_node: root :: 找到让人类长生不老的方法
========== TRANSCRIPT ==========
→ call task_view({"max_depth":5})
【tool:task_view】
{"ok": true, "tree": "GOAL: 找到让人类长生不老的方法\n► [✓ done ] root: 找到让人类长生不老的方法\n├─ [✓ done ] n1: 建立 marker 锚定后的局部交换判定框架 ← 已完成 marker 锚定后的局部交换判定框架：固定 μ 锚点、排除触及 μ 的交换、用 greedy witness span 压缩候选窗口，并在触及 wit\n│ ├─ [✓ done ] n5: 规范化 witness：固定 μ 锚点并限制一次交换的位置 ← 完成 witness 规范化：确认固定 μ 锚点时必须排除触碰 μ 的交换，并用 greedy witness span 将允许交换压缩到局部窗口内；小规模穷举\n│ │ ├─ [✓ done ] n9: 证伪一次交换跨越 μ 的规范化可能性 ← 用穷举验证并归纳出结构性事实：任何触及唯一 marker μ 的相邻交换都会使 μ 的位置改变 1，因此在固定 μ 位置的 witness 规范化里，不存在“跨\n│ │ ├─ [✓ done ] n10: 把单侧交换位置压缩为可判定窗口 ← 证明并穷举验证：对左块 greedy witness 的最左/最右嵌入位置 p1..pk，窗口外相邻交换不会改变最大前缀消耗 k，因此允许交换位置可压缩为 [p\n│ │ └─ [✓ done ] n11: 沉淀 witness 规范形模板 ← 沉淀出 witness 规范形模板：固定 μ 锚点、排除触及 μ 的交换、以 greedy witness span 限定局部窗口，并用左块最大前缀消耗 k 作\n│ ├─ [✓ done ] n6: 建立单侧切分判定接口：把可行性压成存在切分点 k ← 把固定 μ 锚点后的可行性压成了单侧切分接口：左块只通过最大前缀消耗长度 k 传递，且 k 由 X 决定、与 Y 无关。\n│ ├─ [✓ done ] n7: 刻画交换不依赖右侧的充分条件 ← 验证了一个可复用充分条件：若一次相邻交换不改变对任意 S 的左块最大前缀消耗 k，则对所有右侧 Y 的可行性判定保持不变；并用穷举检查了 small-case \n│ ├─ [✓ done ] n8: 沉淀可复用的验证模板与失败边界 ← 找到验证模板的失败边界：任意 witness span 不够，必须用 greedy witness span；给出反例 X=abb, S=ba，窗口外交换仍可改\n│ ├─ [✓ done ] n12: 探索两次相邻交换下 greedy witness span 的局部性边界 ← 在二元字母表、长度 n<=8 的穷举中，未找到“两个相邻交换都发生在原始 greedy witness span 之外却改变 k”的反例；这给出了多交换局部性边\n│ ├─ [✓ done ] n13: 把 marker 锚定后的局部交换判定落实为可执行的 O(n)~O(n log n) 检查流程 ← 完成了一个可执行的局部交换检查流程：先算 k，再用 greedy witness span 的局部闭包限制候选交换；对二元字母表、|X|<=8、|S|<=8 的\n│ ├─ [✓ done ] n14: 证伪 greedy witne
→ call search_memory({"limit":5,"mission_only":false,"query":"OSK senolytic head-to-head 同组织 同终点 证据缺失 边界"})
→ call search_memory({"limit":5,"mission_only":false,"query":"比较证据缺失边界 head-to-head 代理证据 同研究 同组织 同读出"})
【tool:search_memory】
{"ok": true, "results": [{"title": "骨组织中 OSK vs senolytic 的比较证据缺失边界", "tags": "lesson failure evidence-chain [[[[无 head-to-head 就不要做路线优劣结论]]]]", "mission": "", "modified": "20260425164526000", "preview": "!! 骨组织中 OSK vs senolytic 的比较证据缺失边界 ''结论'': 当在骨组织里检索 [[OSK]] / [[partial reprogramming]] 与 [[senolytic]]（如 navitoclax / ABT-263）时，若 PubMed 只能分别检到各自正例而检不到同研究、同组织、同终点的直接原始对照，就应把结论降级为“比较证据缺失”，而不是推出路线优劣。 !! 检索启示 网页检索若遇到网络不可达，不能当作证据链补全；此时应把任务切成更小的可比代理问题，例如先确认骨组织中各自的原始终点，再比较终点类型是否可对齐。"}, {"title": "OSK vs senolytic 的最小可比实验规格", "tags": "fact method principle 4360dd15", "mission": "", "modified": "20260425022856000", "preview": "!! OSK vs senolytic 的最小可比实验规格 当两个抗衰老路线（例如 [[partial reprogramming]]/OSK 与 [[senolytic]]/ABT-263）在同一组织里只有''并列正例''、没有''同研究 head-to-head''时，最小可比实验不应追求先验“同剂量”或“同递送方式”，而应追求''同组织 + 同年龄背景 + 同功能挑战 + 同安全读出''。 !! 适用场景 # 证据地图已经显示两条路线各自在同组织有效，但缺少直接比较。 # 目标是把“比较证据缺失”转化成一个可执行的下一步实验规范。 !! 皮肤场景下的最小规格 # ''组织'': aged dorsal skin # ''背景'': 同品系、同性别、同龄（例如 24 月龄） # ''功能挑战'': 标准化伤口模型（同一尺寸、同一创建时点） # ''主读出'': wound clos"}, {"title": "OSK vs senolytic direct head-to-head remains sparse across tissues", "tags": "lesson method fact 4360dd15", "mission": "", "modified": "20260425022737000", "preview": "!! OSK vs senolytic 的直接 head-to-head 在多组织扫描中仍极稀缺 ''经验性结论'': 当把检索范围从皮肤扩展到视网膜、肾脏、心脏、骨骼肌和脑，并且同时限定 `OSK/OSKM/partial reprogramming` 与 `senolytic/ABT-263/navitoclax` 时，PubMed 检索仍然没有稳定命中同一原始研究中的直接 head-to-head。 ''可复用方法'': # 先用一个组织做证据地图；若没有头对头，再横向扫多个高概率组织。 # 若跨组织扫描仍只得到各自正例而无同研究比较，应把结论降级为“比较证据
【tool:search_memory】
{"ok": true, "results": [{"title": "骨组织中 OSK vs senolytic 的比较证据缺失边界", "tags": "lesson failure evidence-chain [[[[无 head-to-head 就不要做路线优劣结论]]]]", "mission": "", "modified": "20260425164526000", "preview": "!! 骨组织中 OSK vs senolytic 的比较证据缺失边界 ''结论'': 当在骨组织里检索 [[OSK]] / [[partial reprogramming]] 与 [[senolytic]]（如 navitoclax / ABT-263）时，若 PubMed 只能分别检到各自正例而检不到同研究、同组织、同终点的直接原始对照，就应把结论降级为“比较证据缺失”，而不是推出路线优劣。 !! 检索启示 网页检索若遇到网络不可达，不能当作证据链补全；此时应把任务切成更小的可比代理问题，例如先确认骨组织中各自的原始终点，再比较终点类型是否可对齐。"}, {"title": "无 head-to-head 就不要做路线优劣结论", "tags": "lesson principle failure", "mission": "4360dd15", "modified": "20260425022753000", "preview": "比较两条路线时，若跨组织扫描仍只能找到各自正例而找不到同研究、同组织、同读出的直接 head-to-head，就应把结论降级为“比较证据缺失”。没有可比设计时，不能从并列正例推导出路线优劣。"}, {"title": "OSK vs senolytic 的最小可比实验规格", "tags": "fact method principle 4360dd15", "mission": "", "modified": "20260425022856000", "preview": "!! OSK vs senolytic 的最小可比实验规格 当两个抗衰老路线（例如 [[partial reprogramming]]/OSK 与 [[senolytic]]/ABT-263）在同一组织里只有''并列正例''、没有''同研究 head-to-head''时，最小可比实验不应追求先验“同剂量”或“同递送方式”，而应追求''同组织 + 同年龄背景 + 同功能挑战 + 同安全读出''。 !! 适用场景 # 证据地图已经显示两条路线各自在同组织有效，但缺少直接比较。 # 目标是把“比较证据缺失”转化成一个可执行的下一步实验规范。 !! 皮肤场景下的最小规格 # ''组织'': aged dorsal skin # ''背景'': 同品系、同性别、同龄（例如 24 月龄） # ''功能挑战'': 标准化伤口模型（同一尺寸、同一创建时点） # ''主读出'': wound clos"}, {"title": "皮肤中 OSK vs ABT-263 的原始 head-to-head 未检到", "tags": "lesson fact method 4360dd15", "mission": "", "modified": "20260425022429000", "preview": "!! 皮肤中 OSK vs ABT-263 的原始 head-to-head 目前未检到 ''检索结论'': 以 skin / dorsal s
→ call task_add({"parent_id":"root","rationale":"当前骨组织里已确认缺少 OSK vs senolytic 的直接 head-to-head；下一步应把“比较证据缺失”转成最小可比代理终点的可执行方案，以便判断后续实验/检索是否能对齐同研究、同组织、同读出。","title":"在骨组织里定义 OSK 与 senolytic 可对齐的最小代理终点"})
【tool:task_add】
{"ok": true, "id": "n145", "parent": "root", "title": "在骨组织里定义 OSK 与 senolytic 可对齐的最小代理终点", "status": "pending"}
→ call task_focus({"id":"n145"})
【tool:task_focus】
{"ok": true, "focused": "n145", "title": "在骨组织里定义 OSK 与 senolytic 可对齐的最小代理终点", "status": "in_progress", "path": ["找到让人类长生不老的方法", "在骨组织里定义 OSK 与 senolytic 可对齐的最小代理终点"]}
→ call pubmed_search({"limit":10,"query":"(bone OR skeletal OR osteoblast OR osteocyte OR cartilage OR bone marrow) (OSK OR OSKM OR partial reprogramming OR Yamanaka) (senolytic OR ABT-263 OR navitoclax)"})
→ call web_search({"limit":8,"query":"bone OSK partial reprogramming senolytic ABT-263 navitoclax head-to-head"})
→ call pubmed_search({"limit":10,"query":"bone senolytic ABT-263 navitoclax osteoblast osteocyte cartilage wound regeneration"})
→ call pubmed_search({"limit":10,"query":"bone partial reprogramming OSK osteoblast osteocyte cartilage age reversal"})
【tool:pubmed_search】
{"ok": true, "query": "(bone OR skeletal OR osteoblast OR osteocyte OR cartilage OR bone marrow) (OSK OR OSKM OR partial reprogramming OR Yamanaka) (senolytic OR ABT-263 OR navitoclax)", "results": [{"pmid": "40642939", "title": "Biomarkers of aging as it relates osteoarthritis: we can't improve what we can't measure.", "source": "Connect Tissue Res", "pubdate": "2025 Sep", "authors": ["Diekman BO", "Hsueh MF"], "url": "https://pubmed.ncbi.nlm.nih.gov/40642939/"}, {"pmid": "39210148", "title": "ImAge quantitates aging and rejuvenation.", "source": "Nat Aging", "pubdate": "2024 Sep", "authors": ["Alvarez-Kuglen M", "Ninomiya K", "Qin H", "Rodriguez D", "Fiengo L", "Farhy C", "Hsu WM", "Kirk B"], "url": "https://pubmed.ncbi.nlm.nih.gov/39210148/"}]}
【tool:web_search】
{"ok": false, "error": "[Errno 101] Network is unreachable"}
【tool:pubmed_search】
{"ok": true, "query": "bone senolytic ABT-263 navitoclax osteoblast osteocyte cartilage wound regeneration", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "bone partial reprogramming OSK osteoblast osteocyte cartilage age reversal", "results": []}
→ call web_fetch({"max_chars":5000,"url":"https://pubmed.ncbi.nlm.nih.gov/40642939/"})
→ call web_fetch({"max_chars":5000,"url":"https://pubmed.ncbi.nlm.nih.gov/39210148/"})
【tool:web_fetch】
{"ok": true, "url": "https://pubmed.ncbi.nlm.nih.gov/40642939/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Biomarkers of aging as it relates osteoarthritis: we can't improve what we can't measure - PubMed Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content An official website of the United States government Here's how you know The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Log in Show account info Close Account Logged in as: username Dashboard Publications Account settings Log out Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard User Guide Save Email Send to Clipboard My Bibliography Collections Citation manager Display options Display options Format Abstract PubMed PMID Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel Email citation Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel Add to Collections Create a new
【tool:web_fetch】
{"ok": true, "url": "https://pubmed.ncbi.nlm.nih.gov/39210148/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "ImAge quantitates aging and rejuvenation - PubMed Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content An official website of the United States government Here's how you know The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Log in Show account info Close Account Logged in as: username Dashboard Publications Account settings Log out Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard User Guide Save Email Send to Clipboard My Bibliography Collections Citation manager Display options Display options Format Abstract PubMed PMID Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel Email citation Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel Add to Collections Create a new collection Add to an existing collection Name your collect
→ call pubmed_search({"limit":10,"query":"osteoarthritis biomarkers aging rejuvenation DNA methylation bone biomarkers review"})
→ call pubmed_search({"limit":10,"query":"bone senescence markers p16 p21 SASP osteoarthritis review"})
→ call pubmed_search({"limit":10,"query":"osteoporosis biomarkers aging DNA methylation bone age clock review"})
【tool:pubmed_search】
{"ok": true, "query": "osteoarthritis biomarkers aging rejuvenation DNA methylation bone biomarkers review", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "bone senescence markers p16 p21 SASP osteoarthritis review", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "osteoporosis biomarkers aging DNA methylation bone age clock review", "results": [{"pmid": "40409455", "title": "The application of epigenetic clocks in degenerative musculoskeletal diseases: A systematic review.", "source": "Osteoarthritis Cartilage", "pubdate": "2025 Sep", "authors": ["Bao C", "Zhu W", "Bao T", "Hou Y", "Wu T", "Huang J", "He C"], "url": "https://pubmed.ncbi.nlm.nih.gov/40409455/"}]}
→ call search_memory({"limit":5,"mission_only":false,"query":"最小代理终点 骨组织 OSK senolytic 比较证据缺失"})
【tool:search_memory】
{"ok": true, "results": [{"title": "骨组织中 OSK vs senolytic 的比较证据缺失边界", "tags": "lesson failure evidence-chain [[[[无 head-to-head 就不要做路线优劣结论]]]]", "mission": "", "modified": "20260425164526000", "preview": "!! 骨组织中 OSK vs senolytic 的比较证据缺失边界 ''结论'': 当在骨组织里检索 [[OSK]] / [[partial reprogramming]] 与 [[senolytic]]（如 navitoclax / ABT-263）时，若 PubMed 只能分别检到各自正例而检不到同研究、同组织、同终点的直接原始对照，就应把结论降级为“比较证据缺失”，而不是推出路线优劣。 !! 检索启示 网页检索若遇到网络不可达，不能当作证据链补全；此时应把任务切成更小的可比代理问题，例如先确认骨组织中各自的原始终点，再比较终点类型是否可对齐。"}, {"title": "OSK vs senolytic 的最小可比实验规格", "tags": "fact method principle 4360dd15", "mission": "", "modified": "20260425022856000", "preview": "!! OSK vs senolytic 的最小可比实验规格 当两个抗衰老路线（例如 [[partial reprogramming]]/OSK 与 [[senolytic]]/ABT-263）在同一组织里只有''并列正例''、没有''同研究 head-to-head''时，最小可比实验不应追求先验“同剂量”或“同递送方式”，而应追求''同组织 + 同年龄背景 + 同功能挑战 + 同安全读出''。 !! 适用场景 # 证据地图已经显示两条路线各自在同组织有效，但缺少直接比较。 # 目标是把“比较证据缺失”转化成一个可执行的下一步实验规范。 !! 皮肤场景下的最小规格 # ''组织'': aged dorsal skin # ''背景'': 同品系、同性别、同龄（例如 24 月龄） # ''功能挑战'': 标准化伤口模型（同一尺寸、同一创建时点） # ''主读出'': wound clos"}, {"title": "OSK vs senolytic direct head-to-head remains sparse across tissues", "tags": "lesson method fact 4360dd15", "mission": "", "modified": "20260425022737000", "preview": "!! OSK vs senolytic 的直接 head-to-head 在多组织扫描中仍极稀缺 ''经验性结论'': 当把检索范围从皮肤扩展到视网膜、肾脏、心脏、骨骼肌和脑，并且同时限定 `OSK/OSKM/partial reprogramming` 与 `senolytic/ABT-263/navitoclax` 时，PubMed 检索仍然没有稳定命中同一原始研究中的直接 head-to-head。 ''可复用方法'': # 先用一个组织做证据地图；若没有头对头，再横向扫多个高概率组织。 # 若跨组织扫描仍只得到各自正例而无同研究比较，应把结论降级为“比较证据
→ call pubmed_search({"limit":10,"query":"epigenetic clocks musculoskeletal disease systematic review bone"})
→ call pubmed_search({"limit":10,"query":"bone age clock epigenetic clock skeletal tissue review"})
→ call pubmed_search({"limit":10,"query":"osteoarthritis aging biomarkers methylation clock review bone"})
【tool:pubmed_search】
{"ok": true, "query": "epigenetic clocks musculoskeletal disease systematic review bone", "results": [{"pmid": "40409455", "title": "The application of epigenetic clocks in degenerative musculoskeletal diseases: A systematic review.", "source": "Osteoarthritis Cartilage", "pubdate": "2025 Sep", "authors": ["Bao C", "Zhu W", "Bao T", "Hou Y", "Wu T", "Huang J", "He C"], "url": "https://pubmed.ncbi.nlm.nih.gov/40409455/"}]}
【tool:pubmed_search】
{"ok": true, "query": "bone age clock epigenetic clock skeletal tissue review", "results": [{"pmid": "36901968", "title": "Frailty and the Interactions between Skeletal Muscle, Bone, and Adipose Tissue-Impact on Cardiovascular Disease and Possible Therapeutic Measures.", "source": "Int J Mol Sci", "pubdate": "2023 Feb 25", "authors": ["Soto ME", "Pérez-Torres I", "Rubio-Ruiz ME", "Cano-Martínez A", "Manzano-Pech L", "Guarner-Lans V"], "url": "https://pubmed.ncbi.nlm.nih.gov/36901968/"}, {"pmid": "33634751", "title": "Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1).", "source": "Autophagy", "pubdate": "2021 Jan", "authors": ["Klionsky DJ", "Abdel-Aziz AK", "Abdelfatah S", "Abdellatif M", "Abdoli A", "Abel S", "Abeliovich H", "Abildgaard MH"], "url": "https://pubmed.ncbi.nlm.nih.gov/33634751/"}]}
【tool:pubmed_search】
{"ok": true, "query": "osteoarthritis aging biomarkers methylation clock review bone", "results": [{"pmid": "40409455", "title": "The application of epigenetic clocks in degenerative musculoskeletal diseases: A systematic review.", "source": "Osteoarthritis Cartilage", "pubdate": "2025 Sep", "authors": ["Bao C", "Zhu W", "Bao T", "Hou Y", "Wu T", "Huang J", "He C"], "url": "https://pubmed.ncbi.nlm.nih.gov/40409455/"}]}
→ call write_note({"tags":["fact","method","principle","[[骨组织中 OSK vs senolytic 的比较证据缺失边界]]","[[OSK vs senolytic 的最小可比实验规格]]"],"text":"!! 骨组织中 OSK 与 senolytic 的最小代理终点\n''结论'': 当骨组织里找不到 [[OSK]] / [[partial reprogramming]] 与 [[senolytic]] 的直接 head-to-head 原始研究时，最小可比方案不应先争论“谁更强”，而应先定义一组能被两条路线共同影响的代理终点。\n\n!! 代理终点的最小分层\n# ''层 1：年龄/重juvenation 信号'' —— 优先用可量化的衰老回退指标，例如表观遗传时钟、年龄加速（age acceleration）或类似 [[ImAge quantitates )
【tool:write_note】
{"ok": true, "path": "/root/Sisyphus/wiki/tiddlers/骨组织中_OSK_与_senolytic_的最小代理终点.tid", "title": "骨组织中 OSK 与 senolytic 的最小代理终点"}
→ call task_done({"id":"n145","result":"定义了骨组织中 OSK 与 senolytic 可对齐的最小代理终点分层：年龄/重juvenation、组织功能、安全/身份三层，并将其锚定到比较证据缺失边界与肌骨 aging clock 文献。"})
【tool:task_done】
{"ok": true, "id": "n145", "status": "done", "next_focus": "root"}
【assistant】
本轮已完成：
- 新增并写入长期记忆：**骨组织中 OSK 与 senolytic 的最小代理终点**
- 用 PubMed 侧证了骨/肌骨领域已有 **epigenetic clocks / aging biomarkers** 进入可测量框架
- 将骨组织里 OSK vs senolytic 的比较，从“路线优劣”降级为：
1. 年龄/重juvenation 代理终点
2. 骨组织功能终点
3. 安全/身份终点
关键结论：
- **没有同研究、同组织、同读出 head-to-head 时，先对齐代理终点，再谈比较。**
- 这条规则已经和既有的“比较证据缺失边界”接上了。
<NEXT_FOCUS>把骨组织的最小代理终点进一步落成一个可执行的同研究比较模板：明确候选读出、优先级、以及 go/no-go 判据。</NEXT_FOCUS>
========== REFLECTION ==========
{
"progress": "确认了骨组织里 OSK 与 senolytic 仍缺同研究、同组织、同终点的直接对照；当前只能把问题推进到“可对齐的最小代理终点”层面。",
"failure": "只检到综述/方法类条目，没拿到骨组织中可用于 OSK 与 senolytic 直接比较的原始终点证据，且网页检索还遭遇网络不可达。",
"empirical_actions": "调用了 task_view、search_memory、task_add、task_focus、4 次 pubmed_search、2 次 web_search、2 次 web_fetch 和再次 search_memory；外部新数据仅有 PubMed 命中 40642939、39210148、40409455 这类综述/测量方法文章，未发现骨组织中 OSK vs senolytic 的直接原始对照。",
"lesson": {
"worthy": false,
"title": "",
"extends_existing": "",
"tags": [],
"text": ""
},
"next_focus": "只锁定一个骨组织最小代理终点，验证它是否能在 OSK 与 senolytic 两侧都找到原始研究读出。"
}